Efficacy of nebulized budesonide in treatment of severe infantile asthma: A double-blind study☆,☆☆,★
Section snippets
METHODS
Infants were recruited for study from Hôpital des Enfants Malades, Paris, France between December 1991 and February 1992.
Diagnosis of asthma was defined by at least three exacerbations of dyspnea associated with wheezing during the 12 months before the study. Severe asthma was defined as either one exacerbation per month requiring oral steroid administration during the 3 months before inclusion in the study or persistent asthma with daily symptoms for at least 15 days before inclusion. Informed
RESULTS
Forty patients, 35 boys and 5 girls, with a mean age of 17 months (range, 6 to 30 months) were recruited for study. Thirty-five patients completed the 12-week treatment period; three patients were withdrawn prematurely: one was withdrawn because of lack of efficacy (placebo group), one was lost to follow-up (placebo group), and one could not tolerate the device (budesonide group). Two patients in the placebo group were excluded from the analysis because they had no data apart from the data
DISCUSSION
Our results provide evidence that the administration of 1 mg of nebulized budesonide twice daily for 12 weeks was an effective treatment for severe asthma in children younger than 30 months of age. Significantly fewer patients in the budesonide group had exacerbations requiring administration of oral corticosteroids, and for those who had such exacerbations, the duration of oral corticosteroid therapy decreased. The incidence of daytime and nighttime wheezing was lower in the budesonide group
Acknowledgements
We thank Madeline Frame, of ASTRA International Medical Services, Hemel Hempstead, England, for reviewing the manuscript.
References (34)
- et al.
Infantile bronchial asthma
J ALLERGY CLIN IMMUNOL
(1981) - et al.
Inhaled budesonide for treatment of recurrent wheezing in early childhood
Lancet
(1990) - et al.
Nebulised budesonide in severe infantile asthma
Lancet
(1987) - et al.
Reduction of budesonide after a year of increased use: a randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintained
J ALLERGY CLIN IMMUNOL
(1991) - et al.
Efficacy of albuterol administered by nebulizer versus spacer device in children with acute asthma
J Pediatr
(1993) Is the MDI doomed to extinction?
Chest
(1993)- et al.
Disposable jet nebulizers. How reliable are they?
Chest
(1992) - et al.
Effects of long term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children
Respir Med
(1994) Wheezy bronchitis revisited
Arch Dis Child
(1989)Inhaled topical corticosteroid in the first two years of life
Eur Respir Rev
(1993)
Clinical observations of nebulized flunisolide in infants and young children with asthma and bronchopulmonary dysplasia
Pediatr Pulmonol
Nebulized steroid therapy in bronchopulmonary dysplasia
Pediatr Pulmonol
Asthma—a follow-up statement from an international paediatric asthma consensus group
Arch Dis Child
Nebulised beclomethasone dipropionate in recurrent obstructive episodes after acute bronchiolitis
Arch Dis Child
Aerolized budesonide in asthmatic infants: a double blind study
Pediatr Pulmonol
Inhaled budesonide for chronic wheezing under 18 months of age
Arch Dis Child
Treatment of severe steroid dependent preschool asthma with nebulised budesonide suspension
Arch Dis Child
Cited by (137)
The safety of long-term use of inhaled corticosteroids in patients with asthma: A systematic review and meta-analysis
2022, Clinical ImmunologyCitation Excerpt :The P value of Begg's rank correlation test (STATA 12.0) was used to assess the presence of publication bias in included articles for each outcome. Of 17,234 trials recognized by the initial search, 331 were retrieved for more detailed assessment, and 86 trials [8–91,105–107] were included in the meta-analysis (Fig. 1). Baseline characteristics of trials included in the meta-analysis are shown in Table 1.
Nebulized Inhaled Corticosteroids in Asthma Treatment in Children 5 Years or Younger: A Systematic Review and Global Expert Analysis
2020, Journal of Allergy and Clinical Immunology: In PracticeCitation Excerpt :One investigation found a significant decrease in serum cortisol level after intravenous prednisolone treatment (P = .0036), highlighting one of the key advantages of nebulized administration of corticosteroids in acute asthma therapy.17 Nine articles from 8 studies published between 1996 and 2013, and including a total of 1681 children, were identified (Table III).9,24-31 Nebulized budesonide was the focus in all these trials.
Ciclesonide and budesonide suspensions for nebulization delivery: An in vivo inhalation biopharmaceutics investigation
2018, International Journal of PharmaceuticsCitation Excerpt :Although the use of the former two handheld inhalers is highly prevalent in routine clinical practice, the administration of ICS via nebulizers has certain advantages in various settings (Melani, 2012). For example, effective drug delivery with nebulizers requires no coordinate inhalation and less intensive patient training, and hence young children, the elderly, some critically ill patients and those with restricted dexterity could be in compliance with nebulized therapy (de Blic et al., 1996; Boe et al., 2001). Nebulized ICS, including budesonide, beclomethasone dipropionate, flunisolide and fluticasone propionate, are approved in both children and adults for the treatment of asthma and moderate-to-severe COPD, including use during exacerbations, in more than 70 countries worldwide (Melani, 2012).
Special Considerations for Infants and Young Children
2016, Pediatric Allergy: Principles and Practice: Third EditionDifficult Childhood Asthma. Management and Future
2012, Clinics in Chest MedicineInhalation devices: Characteristics, modeling, regulation and use in routine practice. GAT Aerosolstorming, Paris 2011
2012, Revue des Maladies Respiratoires
- ☆
From aHôpital des Enfants Malades, Paris; bLaboratoires ASTRA-FRANCE, Nanterre; and cASTRA International Medical Services, Hemel, Hempstead.
- ☆☆
Reprint requests: Jacques de Blic, MD, Service de Pneumologie et d’Allergologie Pédiatriques, Hôpital des Enfants Malades, 149 rue de Sèvres, 75730 Paris Cedex 15, France.
- ★
1/1/67340